These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 33228017)

  • 21. Dapagliflozin in peritoneal dialysis patients: a pilot study evaluating peritoneal membrane function.
    Hamdan Z; Abdel-Hafez Y; Enaya A; Sarsour A; Kharraz L; Nazzal Z
    BMC Nephrol; 2024 Jan; 25(1):37. PubMed ID: 38279109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibiting core fucosylation attenuates glucose-induced peritoneal fibrosis in rats.
    Li L; Shen N; Wang N; Wang W; Tang Q; Du X; Carrero JJ; Wang K; Deng Y; Li Z; Lin H; Wu T
    Kidney Int; 2018 Jun; 93(6):1384-1396. PubMed ID: 29571940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preservation of peritoneal morphology and function by pentoxifylline in a rat model of peritoneal dialysis: molecular studies.
    Hung KY; Huang JW; Chiang CK; Tsai TJ
    Nephrol Dial Transplant; 2008 Dec; 23(12):3831-40. PubMed ID: 18614818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
    Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
    Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
    Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peritoneal fibrosis and high transport are induced in mildly pre-injured peritoneum by 3,4-dideoxyglucosone-3-ene in mice.
    Yokoi H; Kasahara M; Mori K; Kuwabara T; Toda N; Yamada R; Namoto S; Yamamoto T; Seki N; Souma N; Yamaguchi T; Sugawara A; Mukoyama M; Nakao K
    Perit Dial Int; 2013; 33(2):143-54. PubMed ID: 23123666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.
    Cassis P; Locatelli M; Cerullo D; Corna D; Buelli S; Zanchi C; Villa S; Morigi M; Remuzzi G; Benigni A; Zoja C
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Octreotide lessens peritoneal injury in experimental encapsulated peritoneal sclerosis model.
    Ertilav M; Hur E; Bozkurt D; Sipahi S; Timur O; Sarsik B; Akcicek F; Duman S
    Nephrology (Carlton); 2011 Aug; 16(6):552-7. PubMed ID: 21382127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of neutral-pH dialysis solutions on the peritoneal membrane: a long-term investigation in rats.
    Wieczorowska-Tobis K; Polubinska A; Schaub TP; Schilling H; Wisniewska J; Witowski J; Passlick-Deetjen J; Breborowicz A
    Perit Dial Int; 2001; 21 Suppl 3():S108-13. PubMed ID: 11887803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nebivolol, a β1-adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis.
    Liappas G; González-Mateo G; Aguirre AR; Abensur H; Albar-Vizcaino P; Parra EG; Sandoval P; Ramírez LG; Del Peso G; Acedo JM; Bajo MA; Selgas R; Sánchez Tomero JA; López-Cabrera M; Aguilera A
    Oncotarget; 2016 May; 7(21):30133-46. PubMed ID: 27102153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ST2 blockade mitigates peritoneal fibrosis induced by TGF-β and high glucose.
    Kim YC; Kim KH; Lee S; Jo JW; Park JY; Park MS; Tsogbadrakh B; Lee JP; Lee JW; Kim DK; Oh KH; Jang IJ; Kim YS; Cha RH; Yang SH
    J Cell Mol Med; 2019 Oct; 23(10):6872-6884. PubMed ID: 31397957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damage.
    Loureiro J; Aguilera A; Selgas R; Sandoval P; Albar-Vizcaíno P; Pérez-Lozano ML; Ruiz-Carpio V; Majano PL; Lamas S; Rodríguez-Pascual F; Borras-Cuesta F; Dotor J; López-Cabrera M
    J Am Soc Nephrol; 2011 Sep; 22(9):1682-95. PubMed ID: 21742730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated expression of HDAC6 in clinical peritoneal dialysis patients and its pathogenic role on peritoneal angiogenesis.
    Shi Y; Ni J; Tao M; Ma X; Wang Y; Zang X; Hu Y; Qiu A; Zhuang S; Liu N
    Ren Fail; 2020 Nov; 42(1):890-901. PubMed ID: 32862739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
    Karg MV; Bosch A; Kannenkeril D; Striepe K; Ott C; Schneider MP; Boemke-Zelch F; Linz P; Nagel AM; Titze J; Uder M; Schmieder RE
    Cardiovasc Diabetol; 2018 Jan; 17(1):5. PubMed ID: 29301520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of General Control Nonderepressible-2 Kinase Ameliorates Glucotoxicity in Human Peritoneal Mesothelial Cells, Preserves Their Integrity, and Prevents Mesothelial to Mesenchymal Transition.
    Eleftheriadis T; Pissas G; Antoniadi G; Nikolaou E; Golfinopoulos S; Liakopoulos V; Stefanidis I
    Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31817562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcitriol decreases TGF-β1 and angiotensin II production and protects against chlorhexide digluconate-induced liver peritoneal fibrosis in rats.
    Lee CJ; Subeq YM; Lee RP; Liou HH; Hsu BG
    Cytokine; 2014 Jan; 65(1):105-18. PubMed ID: 24210651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dapagliflozin suppressed gastric cancer growth via regulating OTUD5 mediated YAP1 deubiquitination.
    Ren K; Wang X; Ma R; Chen H; Min T; Ma Y; Xie X; Wang W; Deng X; Zhou Z; Li K; Zhu K; Hao N; Dang C; Sun T; Zhang H
    Eur J Pharmacol; 2024 Nov; 983():177002. PubMed ID: 39293571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.
    Koyani CN; Plastira I; Sourij H; Hallström S; Schmidt A; Rainer PP; Bugger H; Frank S; Malle E; von Lewinski D
    Pharmacol Res; 2020 Aug; 158():104870. PubMed ID: 32434052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A unifying model of glucotoxicity in human renal proximal tubular epithelial cells and the effect of the SGLT2 inhibitor dapagliflozin.
    Eleftheriadis T; Pissas G; Tsogka K; Nikolaou E; Liakopoulos V; Stefanidis I
    Int Urol Nephrol; 2020 Jun; 52(6):1179-1189. PubMed ID: 32361978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.